Analytical HPLC of IIS Analytical HPLC of IIS [98% purity, tR (Method A)= 12.6 min] [97% purity, tR (Method B)= 9.7 min] Analytical HPLC of IIY Analytical HPLC of IIY [98% purity, tR (Method A)= 16.8 min] [97% purity, tR (Method B)= 10.5 min] Analytical HPLC of IIW Analytical HPLC of IIW [99% purity, tR (Method A)= 14.1 min] [98% purity, tR (Method B)= 9.1 min] Analytical HPLC of IIH Analytical HPLC of IIH [98% purity, tR (Method A)= 15.9 min] [98% purity, tR (Method B)= 8.8min] Analytical HPLC of IIQ Analytical HPLC of IIQ [99% purity, tR (Method A)= 12.6 min] [99% purity, tR (Method B)= 9.3 min] S18 Analytical HPLC of IIK Analytical HPLC of IIK [97% purity, tR (Method A)= 11.1 min] [97% purity, tR (Method B)= 9.2 min] Analytical HPLC of IIE Analytical HPLC of IIE [98% purity, tR (Method A)= 12.0 min] [99% purity, tR (Method B)= 9.9 min] Analytical HPLC of IIQNBD Analytical HPLC of IIQNBD [96% purity, tR (Method A)= 10.8 min] [96% purity, tR (Method B)= 8.9 min] Analytical HPLC of IIQ∆ Analytical HPLC of IIQ∆ [97% purity, tR (Method A)= 10.7 min] [97% purity, tR (Method B)= 8.4 min]
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Pharmacokinetic assessments
Qualification assay. Analysis was performed on an LC-MS/MS system consisted of a binary LC-30AD delivery pump, a DUG-20A5R vacuum degasser, a CTO-20A column oven, a SIL-30AC auto-sampler, a CBM-20A system controller (Shimadzu, Japan) and an LCMS-8060 mass spectrometer (Shimadzu, Japan). The mobile phase was composed of solvent A (water containing 0.2 % formic acid and 10 mM ammonium formate) and solvent B (acetonitrile contiaining 5% water, 0.2% formic acid and 10 mM ammonium formate ). The chromatographic separation was performed on a CAPCELL PAK C8 column (3 µm, 50 mm × 2.0mm, Shiseido, Japan) at a flow rate of 1.0 mL/min for 4.5 min kept at 40 ℃, using a gradient method of solvent B from 45% to 55% over 1.5 min, from 55% to 100% over 0.25 min and held for 0.25 min, and back to the initial condition over 2 min to equilibrate the colume. The auto-sampler temperature was maintained at 6 °C, and the injection volume was set to 5 µL. The mass spectrometer was equipped with an electrospray ion (ESI) source working in positive ion multiple reaction monitoring (MRM) mode of the transition m/z 969.60→ 129.15 for IIQ. The parameters including nebulizing gas flow, heating gas flow, drying gas flow, interface temperature, desolventizer (DL) temperature, heat block temperature, collision energy, Q1 and Q3 voltage were set at 3.0 L/min, 10 L/min, 10 L/min, 300 °C, 250 °C, 400 °C, -54 eV, -24 V and -14 V, respectively.
Preparation of samples.
By use of a simple protein precipitation method, the test compound was extracted from rat plasma. A stock solution of IIQ was prepared in solvent of 50/50 acetonitrile/ 0.5% trifluoroacetic acid, and diluted to working solutions at serial concentraion ranging from 1 to 500 µg/ mL with the same solvent. Plasma samples for standard curves were prepared by spiking 100 µL of rat plasma with 10 µL of 10% trifluoroacetic acid, 10 µL of various working solutions and 120 µL of acetonitrile (containing 0.5% trifluoroacetic acid and 1% ammonium hydroxide). The mixture was vortexed for 2 min and centrifuged at 20,000 g for 20 min, the supernatant was transferred to auto-sampler vials, and injected into the LC/MS/MS system. Calibration curve for IIQ in plasma were linear in the concentration range of 0.1-100 µg/mL, with correlation coefficients of > 0.990. To each tested plasma sample (100 µL), all the preparation steps were the same as above, except that 10 µL of various working solutions was substituted by 10 µL blank solvent.
In vivo animal test. Three male Sprague-Dawley rats (weight 210 ± 10 g) were purchased from Animal Center of Beijing Institute of Pharmacology and Toxicology. Each rat was dosed with IIQ at 5 mg/kg by i.v. administration. Blood samples were collected into heparin tubes at 0, 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h after administration, and were immediately centrifuged to separate the plasma fractions. The plasma samples obtained were stored at -20 °C until analysis. Concentration-versus-time profiles were obtained for IIQ, and the pharmacokinetic parameters were calculated by DAS version 3.2.8. Data were averaged and reported as mean ± standard deviation.
Aqueous solubility determination
Solubility was measured by using an HPLC-UV method. IIQ peptide (~2 mg) was added to 1.5-mL Eppendorf tubes and double-distilled H 2 O (ddH 2 O) (100 µL) was added for dissolution with shaking for 24 h at 25 °C, followed by centrifugation of the mixture at 10,000 rpm for 15 min. The saturated supernatant solution was filtered through a 0.45µm filter membrane and then transferred to other vials for analysis by HPLC with UV detection. Each sample was assayed in triplicate. For quantification, analytical RP-HPLC was used with a Zorbax Eclipse XDB-C8 column (4.6 mm × 150 mm, 5 µm). Solvent A: 0.1% TFA in H 2 O; Solvent B: 0.1% TFA in 70% CH 3 CN/H 2 O; flow rate: 1 mL/min; gradient: 5-100% solvent B in solvent A over 25 min. The aqueous concentration was determined by comparison of the S7 peak area of the saturated solution with a standard curve plotted for the peak area versus known concentrations, which was prepared by solutions of test compound in PBS or ddH 2 O at 20, 10, 5, 2.5, 0.5, and 0.05 mg/mL.
HIV-1 Env-mediated cell-cell fusion assay
Cell-cell fusion assays were performed as described earlier. 1 HL2/3 cells, which stably express HIV Gag, Env, Tat, Rev and Nef proteins, and TZM-bl cells, which stably express large amounts of CD4 and CCR5, were obtained from the NIH AIDS Reference and Reagent Program (contributed by Drs. Barbara Felber and George Pavlakis or Drs. John C. Kappes and Xiaoyun Wu, respectively). TZM-bl cells (2.5 × 10 4 /well) and HL2/3 cells (7.5 × 10 4 /well) were coincubated in 96well plates (Corning Costar) at 37°C in 5% CO 2 in the presence of different concentrations of inhibitors. After incubation for 6-8 h, the medium was aspirated, the cells were washed and lysed, and luciferase activity was measured using the Luciferase Assay System (Promega, Madison, WI) on a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA).
Inhibition of pseudotyped Ebola virus infection
Lentivirus-based pseudotyped Sudan Ebola virus was produced as described previously. 2 The Sudan ebola virus pseudovirus and serial dilutions of each peptide were premixed and incubated for 30 min before the mixture was added to the target Huh-7 cells (10 4 per well in 96-well plates). 12 h post-infection, culture medium was replaced with fresh medium. After an additional 72 h, the transduced Huh-7 cells were lysed for the detection of luciferase activity, according to the luciferase assay system manual (Promega, USA). The values of relative light units (RLU) were used to assess the inhibitory activity of peptides.
Hemagglutination inhibition assay
Four times of the HA unit (HAU) of influenza A/Puerto Rico/8/34 virus (25 µL) in U-bottomed 96-well plate was prepared, and then an equal volume (25 µL) of IIQ strated from 100 µM concentration of 3-fold serial dilution in PBS was added into the plate. After 15 min incubation at room temperature, 50 µL of freshly prepared chicken erythrocytes (1% v/v in PBS) were added to each well with multichannel pipettes. Subsequently, the mixture was incubated for 30 min at room temperature to allow for hemagglutination to occur.
Hemolysis inhibition assay
Briefly, the virus stock was diluted with PBS (final titer 10 7 Pfu/mL), and then 100 µL of virus dilution was mix with an equal volume of IIQ solution (20 µM) in a microcentrifuge tube. After 30 min incubation at room temperature, 200 µL of 2% chicken erythrocytes prewarmed at 37 °C was added, followed by incubation for 30 min at 37 °C. 100 µL of sodium acetate (pH 4.6-5.2) was added to above mixture to trigger hemolysis, and then incubation for 30 min at 37 °C. Prior to measure the absorbance of released hemoglobin, the cells were centrifuged at 2000 rpm for 8 min to separate the nonlysed cells. The absorbance of supernatant at OD 535nm was measured by SpectraMax M5 (Molecular Devices, USA). 
